Breast cancer survival in Nordic BRCA2 mutation carriers-unconventional association with oestrogen receptor status

BACKGROUND: The natural history of breast cancer among BRCA2 carriers has not been clearly established. In a previous study from Iceland, positive ER status was a negative prognostic factor. We sought to identify factors that predicted survival after invasive breast cancer in an expanded cohort of B...

Full description

Bibliographic Details
Published in:British Journal of Cancer
Main Authors: Olafsdottir, Elinborg J, Borg, Ake, Jensen, Maj-Britt, Gerdes, Anne-Marie, Johansson, Anna L V, Barkardottir, Rosa B, Johannsson, Oskar T, Ejlertsen, Bent, Sønderstrup, Ida Marie Heeholm, Hovig, Eivind, Lænkholm, Anne-Vibeke, Hansen, Thomas van Overeem, Olafsdottir, Gudridur H, Rossing, Maria, Jonasson, Jon G, Sigurdsson, Stefan, Loman, Niklas, Nilsson, Martin P, Narod, Steven A, Tryggvadottir, Laufey
Format: Article in Journal/Newspaper
Language:English
Published: 2020
Subjects:
Adult
Aged
80 and over
BRCA2 Protein/genetics
Breast Neoplasms/genetics
Female
Genetic Predisposition to Disease
Heterozygote
Humans
Middle Aged
Mutation
Receptors
Estrogen/metabolism
Scandinavian and Nordic Countries
Iceland
Online Access:https://curis.ku.dk/portal/da/publications/breast-cancer-survival-in-nordic-brca2-mutation-carriersunconventional-association-with-oestrogen-receptor-status(1e2f1a9b-6975-41ea-9b2a-367c6688ec0a).html
https://doi.org/10.1038/s41416-020-01056-4
https://curis.ku.dk/ws/files/288874261/Breast_cancer_survival_in_Nordic_BRCA2_mutation_carriers_unconventional_association_with_oestrogen_receptor_status_publisher_version_ccby_.pdf
Description
Summary:BACKGROUND: The natural history of breast cancer among BRCA2 carriers has not been clearly established. In a previous study from Iceland, positive ER status was a negative prognostic factor. We sought to identify factors that predicted survival after invasive breast cancer in an expanded cohort of BRCA2 carriers. METHODS: We studied 608 women with invasive breast cancer and a pathogenic BRCA2 mutation (variant) from four Nordic countries. Information on prognostic factors and treatment was retrieved from health records and by analysis of archived tissue specimens. Hazard ratios (HR) were estimated for breast cancer-specific survival using Cox regression. RESULTS: About 77% of cancers were ER-positive, with the highest proportion (83%) in patients under 40 years. ER-positive breast cancers were more likely to be node-positive (59%) than ER-negative cancers (34%) (P < 0.001). The survival analysis included 584 patients. Positive ER status was protective in the first 5 years from diagnosis (multivariate HR = 0.49; 95% CI 0.26-0.93, P = 0.03); thereafter, the effect was adverse (HR = 1.91; 95% CI 1.07-3.39, P = 0.03). The adverse effect of positive ER status was limited to women who did not undergo endocrine treatment (HR = 2.36; 95% CI 1.26-4.44, P = 0.01) and patients with intact ovaries (HR = 1.99; 95% CI 1.11-3.59, P = 0.02). CONCLUSIONS: The adverse effect of a positive ER status in BRCA2 carriers with breast cancer may be contingent on exposure to ovarian hormones.

Similar Items